In the biological economy of a living organism, oxygen and nutrients are the primary currency. Most healthy tissues have a stable, well-regulated supply line. However, tumors and pathological lesions act as metabolic "black holes," demanding far more resources than the existing local infrastructure can provide. To survive and expand, they must forcibly recruit new supply lines—a process known as angiogenesis.
A broad consensus across recent research suggests that the most effective way to combat these aggressive growths is not necessarily to attack the cells themselves, but to dismantle the infrastructure supporting them. This "starve and freeze" strategy, as described by Li Wang and Wenyu Shi in Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma, shifts the focus from direct cytotoxicity to nutrient deprivation and cell-cycle arrest.
The Molecular Infrastructure of Growth
Angiogenesis is driven by a specific molecular conversation between a hungry tissue and the surrounding vascular network. The primary "request" for more blood is sent via Vascular Endothelial Growth Factor (VEGF). When VEGF binds to its receptors (like VEGFR-2) on nearby blood vessels, it triggers a signaling cascade that tells endothelial cells to migrate, proliferate, and form new tubes.
Research into various compounds—ranging from the antibiotic Azithromycin studied by Fajiu Li in Azithromycin effectively inhibits tumor angiogenesis to the natural extract Broussonetia kazinoki investigated by Young‐Rak Cho in Broussonetia kazinoki modulates the expression of VEGFR-2 and MMP-2—shows that blocking this VEGF/VEGFR axis is the most direct way to halt vessel recruitment. By inhibiting the phosphorylation of these receptors, these treatments prevent endothelial cells from organizing into the functional capillary networks that tumors need to thrive.
Starvation as a Multi-Targeted Strategy
While VEGF is the master regulator, the "starvation" approach is increasingly moving toward multi-target inhibition. Tumors are adaptive; if one signaling pathway is blocked, they often attempt to use others.
- Downregulating Survival Signals: Under low-oxygen (hypoxic) conditions, tumors produce Hypoxia-Inducible Factor 1-alpha (HIF-1α), which further boosts VEGF production. Yuqiong Ding and Hongcheng Zhu have shown that suppressing this HIF-1α/VEGF feedback loop can "prime" tumors, making them more sensitive to other treatments like radiation Improved sensitization effect of sunitinib in cancer cells of the esophagus under hypoxic microenviroment.
- Cutting the "Highways" of Spread: Cancer doesn't just use blood vessels for food; it uses lymphatic vessels as highways for metastasis. Wenhui Ma and Yinlin Ge demonstrated that silencing the protein survivin reduces the density of these lymphatic "highways," effectively trapping the cancer and preventing its spread to other organs Downregulation of survivin expression exerts antitumoral effects on mouse breast cancer cells.
- Disrupting Cellular Adhesion: Beyond just growth factors, the physical "crosstalk" between tumor cells and the blood vessel wall is a target. Li Wang found that the drug Bevacizumab can trigger vessel collapse by blocking the adhesion molecules that usually protect malignant cells during chemotherapy Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells.
Beyond Cancer: Stabilizing the Vascular System
The intuition behind anti-angiogenesis extends beyond oncology into cardiovascular and ocular health. In these contexts, the goal is often to prevent "leaky" or dysfunctional vessels from forming in places they don't belong.
In atherosclerosis, Xiaoyan Yang showed that Ginsenoside Rb1 stabilizes plaques by suppressing the overgrowth of tiny vessels (vasa vasorum) that feed the inflammation within arterial walls Ginsenoside Rb1 Enhances Plaque Stability and Inhibits Adventitial Vasa Vasorum. Similarly, in age-related macular degeneration, Ruoshuang Zhang demonstrated that inhibiting the COX-2 enzyme can simultaneously stop abnormal vessel growth and the resulting scarring that leads to vision loss The COX-2-Selective Antagonist (NS-398) Inhibits Choroidal Neovascularization and Subretinal Fibrosis.
Why the Strategy Works
The reason this approach is so potent is that it targets a fundamental vulnerability of pathological growth: its reliance on external support. By using novel delivery systems—such as the liposomal Quercetin developed by Zhiping Yuan Liposomal Quercetin Efficiently Suppresses Growth of Solid Tumors or the ruthenium nanodrugs created by Yu Lu A Dual-Targeting Ruthenium Nanodrug that Inhibits Primary Tumor Growth and Lung Metastasis—researchers can deliver "molecular brakes" directly to the site of disease.
When these brakes are applied, the result is a quantitative decrease in microvessel density. Without a functional vascular network, the tumor cannot sustain its high metabolic rate. It is essentially "starved" of the oxygen and nutrients required for expansion, and "frozen" in place as its metastatic pathways are dismantled. This shift from killing cells to cutting off their supply lines offers a more precise, often less toxic, way to manage aggressive diseases.